You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Using computational modeling, researchers developed tools that they said will facilitate modeling and correction of genetic diseases by base editing.
NPR reports that the first person in the US to undergo a CRISPR-based treatment for sickle-cell disease continues to do well nearly a year after treatment.
Christiana Care researchers have identified a unique protospacer adjacent motif site that allows them to knock out the NRF2 gene in tumor cells while leaving normal cells alone.
The technique could be used to study DNA repair at high resolution in space, time, and genomic coordinates, the researchers said.
The firms are targeting a compatible offering for single-cell gene expression screens following CRISPR-based editing, with applications in drug discovery.
Three teams have developed base editors that combine the abilities of adenine and cytosine base editors, allowing for concurrent A-to-G and C-to-T edits.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.
The Cambridge, UK-based firm saw double-digit growth in its screening business and declines in its bioproduction and diagnostics businesses.
The company's CRISPR-chrom technology fuses chromatin-modulating peptides to CRISPR nucleases, essentially moving chromatin out of the way for more efficient editing.
In Science this week: genome of a wild wheatgrass that is resistant to fungal disease, and more.
The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.
NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.
Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.